NIGMS PARTICIPATION IN INNOVATIVE TOXICOLOGY MODELS: SBIR/STTR (PA-02-075) Release Date: April 30, 2002 NOTICE: NOT-GM-02-003 National Institute of General Medical Sciences (NIGMS) (http://www.nigms.nih.gov/) The National Institute of General Medical Sciences (NIGMS) will participate in the recently released program announcement PA-02-075 "Innovative Toxicology Models: SBIR/STTR" (http://grants.nih.gov/grants/guide/pa-files/PA-02-075.html). NIGMS has an established interest in understanding interactions of therapeutic drugs or their toxic metabolites with cellular components that may result in the development of toxic effects. This is complementary to the goal of the announcement, namely, the discovery, development and validation of new assays and procedures to determine the toxicological profiles of potential therapeutic drugs. It is expected that a molecular definition of toxicity in the affected organ, tissue or cell would be a component of the procedure. As stated in PA- 02-075, "Approaches for new toxicology assays in response to this initiative are broad and are determined by the creativity of the applicant. Genetically modified animals or cell lines, various non- mammalian organism, in vitro assays utilizing primary mammalian cells (human cells are of particular interest), tissue slices, isolated organs, subcellular fractions, or purified enzymes could be utilized for the model. Computer modeling utilizing existing biological and toxicological data bases would be appropriate. Genomic and proteomic technology could be exploited to profile total gene activity or protein expression and thereby establish molecular correlations with specific toxicities. Molecular endpoints to evaluate toxicity and high throughput toxicity screening could be used to help decide which agent of a chemical series could be pursued, to allow exploration of toxicity at an earlier stage in drug development, to define the toxicity profile of agents selected for clinical trial or for which there is significant environmental exposure." For further information, contact: Richard T. Okita, Ph.D. Pharmacology, Physiology & Biological Chemistry Division, NIGMS 45 Center Drive, Room 2AS-49A Bethesda, MD 20892-6200 Phone: 301-594-1826 Fax: 301-480-2802 Email: okitar@nigms.nih.gov
Weekly TOC for this Announcement
NIH Funding Opportunities and Notices
| ||||||
![]() |
Department of Health and Human Services (HHS) |
![]() |
||||
NIH... Turning Discovery Into Health® |